ZA200904939B - Extended release formulation of nevirapine - Google Patents

Extended release formulation of nevirapine

Info

Publication number
ZA200904939B
ZA200904939B ZA200904939A ZA200904939A ZA200904939B ZA 200904939 B ZA200904939 B ZA 200904939B ZA 200904939 A ZA200904939 A ZA 200904939A ZA 200904939 A ZA200904939 A ZA 200904939A ZA 200904939 B ZA200904939 B ZA 200904939B
Authority
ZA
South Africa
Prior art keywords
nevirapine
release formulation
extended release
formulation
extended
Prior art date
Application number
ZA200904939A
Other languages
English (en)
Inventor
Michael L Cappola
Svetlana Sienkiewicz
Glenn Charles Snow
Feng-Jing Chen
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39739795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200904939(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ZA200904939B publication Critical patent/ZA200904939B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200904939A 2007-06-08 2009-07-15 Extended release formulation of nevirapine ZA200904939B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94276507P 2007-06-08 2007-06-08

Publications (1)

Publication Number Publication Date
ZA200904939B true ZA200904939B (en) 2010-04-28

Family

ID=39739795

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200904939A ZA200904939B (en) 2007-06-08 2009-07-15 Extended release formulation of nevirapine

Country Status (29)

Country Link
US (1) US8460704B2 (de)
EP (1) EP2155169B1 (de)
JP (1) JP5417662B2 (de)
KR (1) KR101017862B1 (de)
CN (1) CN101784263B (de)
AR (1) AR066924A1 (de)
AU (1) AU2008262031B2 (de)
BR (1) BRPI0811732A2 (de)
CA (1) CA2687491C (de)
CL (1) CL2008001678A1 (de)
CO (1) CO6150128A2 (de)
DK (1) DK2155169T3 (de)
EA (1) EA018377B1 (de)
EC (1) ECSP099561A (de)
ES (1) ES2574836T3 (de)
HK (1) HK1145806A1 (de)
HU (1) HUE028598T2 (de)
IL (1) IL199924A0 (de)
MA (1) MA31430B1 (de)
MX (1) MX2009007764A (de)
NZ (1) NZ578664A (de)
PE (2) PE20131035A1 (de)
PL (1) PL2155169T3 (de)
TN (1) TN2009000510A1 (de)
TW (1) TWI419716B (de)
UA (1) UA97971C2 (de)
UY (1) UY31128A1 (de)
WO (1) WO2008154234A2 (de)
ZA (1) ZA200904939B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
MX2009007764A (es) 2007-06-08 2009-09-10 Boehringer Ingelheim Pharma Formulacion de nevirapina de liberacion prolongada.
EP2926825A1 (de) 2008-06-27 2015-10-07 Duke University Therapeutika mit elastinähnlichen peptiden
CA2835272A1 (en) 2011-05-30 2012-12-06 Cipla Limited Pharmaceutical antiretroviral composition
CN104023784B (zh) * 2011-08-24 2018-05-25 费斯生物制药公司 供持续释放的活性剂制剂
IN2014MN01907A (de) * 2012-03-05 2015-07-10 Cipla Ltd
CN104523630B (zh) * 2015-01-22 2017-08-25 山东新时代药业有限公司 一种奈韦拉平片剂
EP3153157A1 (de) 2015-10-09 2017-04-12 Teva Pharmaceutical Works Private Limited Company Pharmazeutische zusammensetzung zur verzögerten freisetzung von nevirapin

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366972A (en) * 1989-04-20 1994-11-22 Boehringer Ingelheim Pharmaceuticals, Inc. 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
CA2030056C (en) 1989-11-17 1995-10-17 Karl D. Hargrave 5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepines and their use in the prevention or treatment of hiv infection
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
US6514530B2 (en) * 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
EP1035834B1 (de) * 1997-12-05 2002-04-17 Alza Corporation Osmotische darreichungsform mit zwei mantelschichten
DE69915346T2 (de) * 1998-12-17 2004-07-22 Alza Corp., Mountain View Umwandlung von flüssigkeitsgefüllten gelatinkapseln in systeme mit gesteuerter wirkstoffabgabe durch mehrfache beschichtungen
HU230440B1 (hu) * 1999-03-31 2016-06-28 Janssen Pharmaceutica N.V Előgélesített keményítőt tartalmazó szabályozott felszabadulású készítmények
EA005423B1 (ru) * 1999-09-24 2005-02-24 Янссен Фармацевтика Н.В. Противовирусные композиции
ES2236012T3 (es) 1999-12-09 2005-07-16 Alza Corporation Medicacion antiviral.
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
WO2002092095A1 (en) 2001-05-11 2002-11-21 Boehringer Ingelheim International Gmbh Use of nevirapine to treat or prevent lipid pathology in patients with hiv that is resistant to nevirapine
US20030050620A1 (en) 2001-09-07 2003-03-13 Isa Odidi Combinatorial type controlled release drug delivery device
AU2003287666A1 (en) 2002-11-13 2004-06-03 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
CA2529852A1 (en) 2003-06-20 2004-12-29 Viral Genomix, Inc. Compositions for and methods for treating hiv
WO2005048978A2 (en) 2003-10-01 2005-06-02 Lupin Limited A controlled release pharmaceutical composition and a process for preparing the same
PL2233112T6 (pl) 2003-11-13 2014-11-28 Psivida Inc Wstrzykiwalny implant o przedłużonym uwalnianiu mający biodegradowalną matrycę i biodegradowalną warstewkę
WO2006024668A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
WO2006114709A1 (en) * 2005-04-25 2006-11-02 Aurobindo Pharma Limited Pharmaceutical compositions of antiretrovirals
AU2006263338A1 (en) 2005-06-29 2007-01-04 Panacea Biotec Ltd. Pharmaceutical sustained release compositions and processes thereof
EP1906937B1 (de) 2005-07-22 2016-10-19 Rubicon Research Pvt Ltd. Neuartige dispergierbare tabletten zusammensetzung
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
WO2007047371A2 (en) * 2005-10-14 2007-04-26 Microdose Technologies, Inc. Pharmaceutical packaging of an oral dosage combination
MX2009007764A (es) 2007-06-08 2009-09-10 Boehringer Ingelheim Pharma Formulacion de nevirapina de liberacion prolongada.

Also Published As

Publication number Publication date
TWI419716B (zh) 2013-12-21
MX2009007764A (es) 2009-09-10
ECSP099561A (es) 2009-09-29
CA2687491A1 (en) 2008-12-18
AU2008262031A1 (en) 2008-12-18
HK1145806A1 (en) 2011-05-06
CA2687491C (en) 2011-09-20
JP5417662B2 (ja) 2014-02-19
WO2008154234A9 (en) 2009-11-26
KR101017862B1 (ko) 2011-03-04
HUE028598T2 (en) 2016-12-28
DK2155169T3 (en) 2016-06-13
JP2010520891A (ja) 2010-06-17
US20100278918A1 (en) 2010-11-04
BRPI0811732A2 (pt) 2014-11-18
WO2008154234A2 (en) 2008-12-18
CN101784263A (zh) 2010-07-21
PE20131035A1 (es) 2013-10-01
EA018377B1 (ru) 2013-07-30
EP2155169B1 (de) 2016-03-23
UY31128A1 (es) 2009-01-30
KR20100020447A (ko) 2010-02-22
AU2008262031B2 (en) 2011-08-25
US8460704B2 (en) 2013-06-11
UA97971C2 (ru) 2012-04-10
PE20090371A1 (es) 2009-04-24
TN2009000510A1 (en) 2011-03-31
ES2574836T3 (es) 2016-06-22
NZ578664A (en) 2011-11-25
AR066924A1 (es) 2009-09-23
PL2155169T3 (pl) 2016-09-30
IL199924A0 (en) 2010-04-15
WO2008154234A3 (en) 2010-01-21
TW200916127A (en) 2009-04-16
MA31430B1 (fr) 2010-06-01
CL2008001678A1 (es) 2009-09-11
EA200900958A1 (ru) 2010-04-30
CN101784263B (zh) 2012-11-07
EP2155169A2 (de) 2010-02-24
CO6150128A2 (es) 2010-04-20

Similar Documents

Publication Publication Date Title
HK1216232A1 (zh) 控釋藥物組合物
IL217153A0 (en) Controlled release formulations
HK1145806A1 (en) Extended release formulation of nevirapine
ZA201004793B (en) Capsule formulation
HK1155712A1 (en) Controlled release of microbiocides
EP2286179A4 (de) Stitching von nahezu genullten subaperturmessungen
IL201008A0 (en) Modified release dosage forms of tacrolimus
IL210149A0 (en) Isolation of cyclopamine
HK1160925A1 (zh) 組織蛋白酶 的用途
EP2296709A4 (de) Niacinformulierungen mit modifizierter freisetzung
GB0822633D0 (en) Formulation
HK1137187A1 (en) Use of tocopherol
EP2413905A4 (de) Formulierung
EP2285219A4 (de) Alprazolamformulierungen mit gesteuerter freisetzung
ZA201004772B (en) Novel formulation
EP2291178A4 (de) Pramipexol-formulierungen mit kontrollierter freisetzung
IL219967A0 (en) Sustained-release formulation
TWI367205B (en) Preparation of paricalcitol
HK1131039A1 (en) Pharmaceutical use of sophoricoside
ZA201004979B (en) Extracts of sclerocarya birrea
GB0814376D0 (en) Formulation
EP2471519A4 (de) Formulierung aus carvedilol mit gesteuerter freisetzung
EP2331490A4 (de) Herstellung von dibutoxymethan
GB0914989D0 (en) Drug release formulations
ZA201001127B (en) Pharmaceutical formulation for extended release